Immunotherapy: adjuvant durvalumab

PreclinicalMonoclonal antibody

Immunotherapy: adjuvant durvalumab is one of 47 small molecule programs targeting NSCLC. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLCRecruiting

NSCLCPreclinical

Recruiting

Competition

Competitive Landscape

55 competitors in NSCLC

#DrugCompanyPhaseTrials

Iressa

AstraZeneca

Approved

3 2

Taxotere

AAvyxa

Phase 3

5 3

Alimta

SShawn Eagle

Phase 3

4 4

Navmi

SSummit Therapeutics

Phase 3

1 5

Taxol

Teva

Phase 2

3 6

Tecentriq

Roche

Phase 2

3 7

Alecensa

Roche

Phase 2

2 8

Libtayo

Regeneron

Phase 2

1 9

Firmonertinib

AAllist Pharmaceuticals, Inc.

Phase 3

2 10

SYS6010

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ARecruiting

NSCLC

NCT06484491

Clinical

Trials by Indication[1]

NSCLC1 trial

IMPT Dose Escalation for NSCLC (HyDose)

Recruiting·UUniversity Medical Center Groningen·N/A·NCT06484491·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immunotherapy: adjuvant durvalumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunotherapy: adjuvant durvalumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunotherapy: adjuvant durvalumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Medical Center Groningen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: UUniversity Medical Center Groningen

Immunotherapy: adjuvant durvalumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

NSCLC1 trial

References

Drug Info

Quick Facts

Related News